Key result
Patients with any mental disorder had higher odds of receiving pharmacological secondary prevention for ischemic heart disease and cerebrovascular disease.
Why the study?
Prior studies evaluating whether patients with comorbid mental illness receive guideline-concordant pharmacological secondary prevention of IHD and CeVD at rates comparable to those without psychiatric diagnoses were few and yielded inconsistent findings.
Does the presence of psychiatric comorbidities affect the receipt of pharmacological secondary prevention in adults with ischemic heart disease or cerebrovascular disease?
Cross-Sectional (n=238,616)
Does the presence of psychiatric comorbidities affect the receipt of pharmacological secondary prevention in adults with ischemic heart disease or cerebrovascular disease?
Patients with comorbid mental disorders have higher prescription rates of pharmacological secondary prevention for IHD and CeVD compared to those without, suggesting other factors drive their excess cardiovascular mortality.
Answers are grounded in this paper and cite their sources.
Potential gaps in secondary prevention for mental illness warrant attention; leaves open whether disparities affect IHD/CeVD outcomes.
Background Individuals with mental disorders face substantially reduced life expectancy, with cardiovascular disease (CVD) as the leading cause of premature death, likely due to a complex interplay of multiple factors. Prior studies examining whether patients with comorbid mental illness receive guideline-concordant pharmacological secondary prevention of ischemic heart disease (IHD) and cerebrovascular disease (CeVD) at rates comparable to those without psychiatric diagnoses are few and yielded inconsistent findings. Methods We conducted a retrospective cross-sectional analysis of statutory health insurance data for 2019–2022 (n = 238,616 adults with IHD or CeVD). Secondary prevention was defined as concurrent prescription of a lipid-modifying agent and an antiplatelet therapy or anticoagulant. Propensity score matching combined with logistic regression was used to estimate adjusted odds ratios (ORs) across all ICD-10 F-chapters (F0–F9) and for severe mental illness (SMI). Results Patients with any mental disorder had significantly higher odds of receiving secondary prevention for IHD (OR 1.18) and CeVD (OR 1.17) than those without. SMI was associated with even higher odds (IHD: OR 1.36; CeVD: OR 1.32). Diagnosis-specific subgroup analysis yielded no substantial differences between different mental disorders. Conclusion In general, prescription rates of pharmacological secondary prevention were higher in patients with comorbid mental disorders compared to patients without mental comorbidity. Factors other than pharmacological undertreatment – such as lifestyle-related prevention and physical health monitoring – may play a more central role in addressing the excess cardiovascular mortality burden in individuals with mental illness.
No takes yet. Share an insight, caveat, or question.
Peters et al. (2026) conducted a cross-sectional in Ischemic heart disease and cerebrovascular disease (n=238,616). Psychiatric comorbidities (any mental disorder) vs. No mental comorbidity was evaluated on Receipt of pharmacological secondary prevention (concurrent prescription of a lipid-modifying agent and an antiplatelet therapy or anticoagulant) for IHD (OR 1.18). Patients with any mental disorder had higher odds of receiving pharmacological secondary prevention for ischemic heart disease and cerebrovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: